| 摘要 |
<p>A composition useful for treating herpes simplex viral infections in humans comprises about 10<2> to 10<8> I.U. of human interferon, about 0.1% to about 20% by weight of an antiviral surface active agent and a physio-logically acceptable carrier. Preferably, the interferon-containing composition comprises about 10<4> to 10<6> I.U. of human leukocyte interferon, about 1% to 5% by weight of a non- ionic surface active agent having at least one ether amide linkage, and a physiologically acceptable carrier. These interferon-containing compositions are useful for treating herpes simplex viral infections in humans by topically administering an effective amount of the above-identified interferon-containing antiherpetic composition to the affected area. Preferably, an effective amount of the interferon-containing anti-herpetic composition is topically administered to the affected area during the prodromal stage of viral multiplication. These interferon-containing compositions are usefully applied to the genital area of a human and, when so applied, would appear to be useful as a prophylactic for or in the treatment of in situ cervical carcinoma, since there is some belief that herpes simplex infection might be a co-carcinogen or a background etio-logical agent which might lead to in situ cervical carcinoma. A special aspect of the use of these interferon-containing compositions is the use of these compositions in the treatment of skin malignancies, pre-malignant skin lesions and skin diseases, such as herpes zoster and psoriasis. These interferon compositions are also useful in the treatment of basal cell carcinoma, squamous cell carcinoma or squamous carcinoma, actinic keratosis and leukoplakia.</p> |
